Seoul, South Korea

Dong Sik Kim

This inventor holds 22 USPTO granted patents and 11 published patent applications, plus 1 CIPO patent and 3 EPO patents, primarily in Antibody Therapeutics. Top assignees: Neuracle Science Co., Ltd., Lg Electronics Inc., Lubrizol Advanced Materials, Inc.. Active years: 2002-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Dong Sik Kim. Retrieved from https://idiyas.com/inventor/dong-sik-kim

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 22 

% Patents Active = 72.7


 

Average Co-Inventor Count = 3.0

ph-index = 6

Forward Citations = 291(Granted Patents)


Location History:

  • Gumi-si, KR (2015)
  • Seoul, KR (2002 - 2024)

Company Filing History:


Years Active: 2002-2025

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Anti-FAM19A5 Antibodies
Glaucoma Treatment
Atherosclerosis
Fibrosis
Neuropathic Pain
Cancer Treatment
Adeno-Associated Virus
Slit Lamp Microscope
IV Flow Controller
Gaming Table Management
Electrostatic Dissipative Properties
Flame Retardant Polyurethanes
22 patents (USPTO):Explore Patents

Title: Inventor Dong Sik Kim: Pioneering Advances in Atherosclerosis Treatment

Introduction

Dong Sik Kim is a prominent inventor based in Seoul, South Korea, recognized for his significant contributions to the field of pharmaceutical sciences. With a remarkable portfolio of 18 patents, Kim has focused his research on innovative treatments aimed at addressing critical health issues.

Latest Patents

Among his latest achievements, Kim has developed two notable patents related to atherosclerosis:

1. **Use of anti-FAM19A5 antibodies for treating atherosclerosis** - This patent discloses the pharmaceutical application of antagonists that specifically bind to FAM19A5. This innovative approach proposes a new method for treating atherosclerosis in individuals requiring intervention.

2. **Adeno-associated virus (AAV) delivery of anti-FAM19A5 antibodies** - This patent introduces adeno-associated virus vectors designed to deliver nucleic acids encoding antagonists against the FAM19A5 protein. This technique facilitates targeted treatment, enhancing the therapeutic efficacy of anti-FAM19A5 antibodies.

Career Highlights

Throughout his career, Dong Sik Kim has worked with reputable organizations such as Neuracle Science Co., Ltd. and LG Electronics Inc. His expertise and dedication to research have significantly impacted the development of effective treatment options in the field of medicine.

Collaborations

Kim's work has often been enhanced through collaboration with notable professionals in the industry. His coworkers Bongcheol Kim and Jae-Keun Lee have shared in the journey of innovation, contributing to the success of various research projects and patents.

Conclusion

Dong Sik Kim exemplifies the spirit of innovation in the scientific community. His dedication to developing groundbreaking treatments for conditions like atherosclerosis has positioned him as a leading inventor in his field. With a strong patent portfolio and a commitment to advancing medical research, Kim continues to pave the way for future discoveries and innovations.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…